Related Experiment Videos

In vitro activation of feline complement by feline leukemia virus

Insights

Normal cat serum poorly inactivates feline leukemia virus (FeLV) by activating complement. This inefficient virolysis may contribute to high FeLV-related leukemia rates in cats.

Area of Science:

  • Immunology
  • Virology
  • Veterinary Medicine

Background:

  • Feline leukemia virus (FeLV) is a significant pathogen in domestic cats.
  • The feline immune system's ability to neutralize FeLV is crucial for disease prevention.

Purpose of the Study:

  • To investigate the complement system's role in feline leukemia virus inactivation.
  • To compare the complement-mediated lysis of FeLV in feline versus human serum.

Main Methods:

  • Incubation of purified FeLV with normal feline and human serum.
  • Assay of complement component consumption (C1, C4, C2, C3).
  • Measurement of complement-dependent FeLV lysis via enzyme release.

Main Results:

  • Normal feline serum activated the complement system's classical pathway upon incubation with FeLV.
  • Complement-dependent lysis of FeLV was significantly less efficient with feline serum compared to human serum.
  • Total hemolytic complement and neutralizing antibody levels did not correlate with virolytic activity in feline sera.

Conclusions:

  • The feline complement system inefficiently lyses FeLV via the classical pathway.
  • Inefficient FeLV virolysis by normal cat serum is a potential factor in the high incidence of feline leukemia.
  • Further research into feline antiviral immunity is warranted.

Related Concept Videos